Disease · MONDO_0005109
Comparisons in its trials473
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 473
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| rIL-2 vs No rIL-2: Grade 4 Signs and Symptoms | 466 of 2,071 | 383 of 2,040 | 4,111 | NCT00004978 | Trial comparisons |
| rIL-2 vs No rIL-2: Number of Participants With Changes in Anti-retroviral Treatment (ART) | 1,760 of 2,071 | 1,751 of 2,040 | 4,111 | NCT00004978 | Trial comparisons |
| rIL-2 vs No rIL-2: Number of Participants Who Died From Any Cause | 107 of 2,071 | 116 of 2,040 | 4,111 | NCT00004978 | Trial comparisons |
| rIL-2 vs No rIL-2: Hepatic, Metabolic, and Cardiac Conditions | 134 of 2,071 | 136 of 2,040 | 4,111 | NCT00004978 | Trial comparisons |
| rIL-2 vs No rIL-2: New or Recurrent Serious HIV Disease Progression Event Including Death | 126 of 2,071 | 130 of 2,040 | 4,111 | NCT00004978 | Trial comparisons |
| rIL-2 vs No rIL-2: New or Recurrent HIV Disease Progression Event Including Death | 159 of 2,071 | 165 of 2,040 | 4,111 | NCT00004978 | Trial comparisons |
| rIL-2 vs No rIL-2: Participants With a New Disease Progression Event or Death | 154 of 2,071 | 164 of 2,040 | 4,111 | NCT00004978 | Trial comparisons |
| rIL-2 vs No rIL-2: serious adverse events | 466 of 2,071 | 383 of 2,040 | 4,111 | NCT00004978 | Trial comparisons |
| rIL-2 vs No rIL-2: Pattern of Use of Prophylaxis for Opportunistic Infections | 54 of 2,028 | 53 of 2,005 | 4,033 | NCT00004978 | Trial comparisons |
| Proleukin Plus Antiretroviral Therapy vs Antiretroviral Therapy Only: New or Recurrent Disease Progression Events, as Defined, or Death. | 110 of 849 | 119 of 846 | 1,695 | NCT00013611 | Trial comparisons |
| Proleukin Plus Antiretroviral Therapy vs Antiretroviral Therapy Only: All-cause Mortality | 81 of 849 | 77 of 846 | 1,695 | NCT00013611 | Trial comparisons |
| Proleukin Plus Antiretroviral Therapy vs Antiretroviral Therapy Only: New or Recurrent Serious Disease Progression Events or Death | 19 of 849 | 28 of 846 | 1,695 | NCT00013611 | Trial comparisons |
| Proleukin Plus Antiretroviral Therapy vs Antiretroviral Therapy Only: New or Recurrent Disease Progression Events | 49 of 849 | 66 of 846 | 1,695 | NCT00013611 | Trial comparisons |
| Proleukin Plus Antiretroviral Therapy vs Antiretroviral Therapy Only: Grade 4 Clinical Events | 203 of 849 | 186 of 846 | 1,695 | NCT00013611 | Trial comparisons |
| Proleukin Plus Antiretroviral Therapy vs Antiretroviral Therapy Only: serious adverse events | 203 of 849 | 186 of 846 | 1,695 | NCT00013611 | Trial comparisons |
| Clinically Driven Monitoring (CDM) vs Laboratory Plus Clinical Monitoring (LCM): LCM vs CDM: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIV | 283 of 606 | 282 of 600 | 1,206 | NCT02028676 | Trial comparisons |
| Clinically Driven Monitoring (CDM) vs Laboratory Plus Clinical Monitoring (LCM): LCM vs CDM: Disease Progression to a New WHO Stage 4 Event or Death | 47 of 606 | 39 of 600 | 1,206 | NCT02028676 | Trial comparisons |
| Clinically Driven Monitoring (CDM) vs Laboratory Plus Clinical Monitoring (LCM): LCM vs CDM, Induction ART: Cessation of First-line Regimen for Clinical/Immunological Failure | 28 of 606 | 35 of 600 | 1,206 | NCT02028676 | Trial comparisons |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD vs LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD: Number of Participants With HIV RNA < 50 c/mL) at Week 96 | 327 of 440 | 302 of 443 | 883 | NCT00272779 | Trial comparisons |
ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD vs LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD: Number of Participants With Confirmed Plasma HIV RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time to Loss of Virologic Response [TLOVR] Algorithm) | 377 of 440 | 363 of 443 | 883 | NCT00272779 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005109/comparisons